Contineum Therapeutics Inc
Contineum Therapeutics Inc (CTNM) Historical Volatility
CTNM's 30 day historical volatility is 155.10%, in the 95th percentile of readings over the past year. This is a high percentile, meaning Contineum Therapeutics Inc shares have swung far more than usual. CTNM's 30 day implied volatility sits at 138.45%, with an IV Rank of 30.95%, leaving IV 16.65 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking CTNM historical volatility helps you see how much Contineum Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CTNM's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CTNM 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CTNM's 30 day historical volatility, or CTNM HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CTNM's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →